Hans Lowenbach, MD Memorial Lecture: Re-Engineering the Future of Neurotechnology in Psychiatry

Sarah Hollingsworth "Holly" Lisanby, MD, DLFAPA, an internationally renowned innovator of neuromodulation technologies, is the founding dean and a tenured professor of the Arizona State University (ASU) School of Medicine and Advanced Medical Engineering and professor emeritus at the Duke University Department of Psychiatry & Behavioral Sciences. Before transitioning to ASU, Dr. Lisanby served as the founding director of the National Institute of Mental Health (NIMH) Division of Translational Research. She played a leading role in the NIH BRAIN Initiative and co-led the Brain Behavior Quantification and Synchronization program. She also founded and directed the NIMH Noninvasive Neuromodulation Unit. Prior to her time at NIH, Dr. Lisanby was chair of Duke's Department of Psychiatry & Behavioral Science and JP Gibbons Endowed Professor with Tenure. She founded and directed both the Duke University and the Columbia University Divisions of Brain Stimulation. An accomplished clinical translational scientist, Dr. Lisanby is internationally known for her pioneering research supporting the FDA approval of novel devices for the treatment of depression, including transcranial magnetic stimulation and vagus nerve stimulation. Continuously NIH-funded for more than 25 years, Dr. Lisanby's research translates knowledge of neurocircuitry underlying brain-based disorders into circuit-targeted therapeutics, informed by mechanisms of treatment resistant neuropsychiatric disorders. ​ Dr. Lisanby has authored more than 300 scientific publications and has received several national and international awards. She serves on the FDA Neurological Devices Advisory Panel and has sat on numerous national and international scientific advisory boards as well as holding leadership positions in several professional organizations. Dr. Lisanby completed her BS, MD, and psychiatry residency at Duke University.